11
Participants
Start Date
December 31, 2012
Primary Completion Date
August 31, 2014
Study Completion Date
March 31, 2016
Rituximab, CMC544, Gemcitabine and Oxaliplatine
"2 cycles of induction of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.~2 cycles of consolidation of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43."
AZ Sint Jan, Bruges
University Hospital Gent, Ghent
CHU de Dijon, Dijon
CHU Pontchaillou, Rennes
CHU Hôtel Dieu, Nantes
CHU Brabois, Vandœuvre-lès-Nancy
CHRU de Lille, Lille
CHU Lyon - Sud, Lyon
Centre Henri Becquerel, Rouen
Hôpital Henri Mondor, Créteil
CHU Mont-Godinne, Yvoir
Collaborators (1)
Pfizer
INDUSTRY
The Lymphoma Academic Research Organisation
OTHER